Highlights
- 1Clinical lymphoma, myeloma & leukemia · 2022
- 2
- 3Annals of hematology · 2022
Publications
123 publications
Clinical research
2 studies
Active
1 study- PINCT05552222A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial TherapyPHASE3 · Janssen Research & Development, LLC · OPEN TO ACCRUAL (as of 2025)Multiple Myeloma
Completed & closed trials (1)
- PINCT06413498A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple MyelomaPHASE3 · Kite Pharma, Inc. · CLOSED TO ACCRUAL (as of 2026)Multiple Myeloma
External relationships
Advisory/Scientific Board Member
GSK Research & Development Limited